Please ensure Javascript is enabled for purposes of website accessibility

Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study

By Brian Orelli, PhD – Feb 10, 2020 at 3:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The results were consistent with a pair of shorter studies of the combination treatment.

Myovant Sciences (MYOV 2.34%) reported positive results from the late-stage Liberty extension study testing its relugolix combination therapy, which contains relugolix, estradiol, and norethindrone acetate, in patients with uterine fibroids.

The biotech had already successfully tested relugolix in two pivotal clinical trials -- dubbed Liberty 1 and 2 -- but those studies only tested how patients responded to the drug for 24 weeks. Since the combination therapy may not be a cure, Myovant Sciences allowed patients from those two studies to enter this extension study, testing it for a total of 52 weeks.

After a year of treatment, 87.7% of the women had responded to the therapy. The drug produced an 89.9% average reduction in menstrual blood loss from baseline.

Myovant plans to submit the results of Liberty 1 and 2 and the extension study to the Food and Drug Administration in April, setting it up for a potential approval late this year or early next year.

Doctor with her hand on a patient's shoulder

Image source: Getty Images.

There's a substantial need for the drug: Approximately 250,000 women in the U.S. undergo hysterectomies to deal with uterine fibroids each year. "A non-invasive treatment option that could provide long-term symptom improvement and ease of use would be a game-changer for physicians and millions of women who suffer from this common condition," Ayman Al-Hendy, professor of obstetrics and gynecology and director of translational research at the University of Illinois College of Medicine, said in the press release announcing the results.

Myovant will run another year-long clinical trial in which patients will either continue to receive the relugolix combination therapy or will be switched to placebo to see if their symptoms return. If the multiyear maintenance therapy continues to help patients, that could increase the potential market for the treatment substantially.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myovant Sciences Ltd. Stock Quote
Myovant Sciences Ltd.
$17.96 (2.34%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.